Cargando…
Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I
Five subjects with mucopolysaccharidosis type I and symptomatic cervical spinal stenosis received intrathecal laronidase in a 4-month pilot study and/or a 12-month extension study [1]. Clinical descriptions of study subjects, nonserious adverse events, individual data tables, and scoring system meth...
Autores principales: | Dickson, P.I., Kaitila, I., Harmatz, P., Mlikotic, A., Chen, A.H., Victoroff, A., Passage, M.B., Madden, J., Le, S.Q., Naylor, D.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573094/ https://www.ncbi.nlm.nih.gov/pubmed/26484358 http://dx.doi.org/10.1016/j.dib.2015.08.004 |
Ejemplares similares
-
Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017) -
The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis()
por: Dualibi, Ana Paula Fiuza Funicello, et al.
Publicado: (2015) -
Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022) -
Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2017) -
Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series
por: Horovitz, Dafne Dain Gandelman, et al.
Publicado: (2016)